RxDoctor Payments Data

Katie Riegle, PA

Physician Assistant · Pensacola, FLNPI 1245509660

Payments from drug & device makers

$6,473in general payments, 2019–2025

Across 371 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$934
  • AbbVie$833
  • Novo Nordisk$617
  • AstraZeneca$608
  • Lilly USA, LLC$489
  • Bayer$303
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$6,473100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,473 in reported general payments places this provider in the 90th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$101,549
Medicare patients
296
Services billed
2,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide43$53,938
OzempicSemaglutide48$49,060
TrulicityDulaglutide15$14,370
EliquisApixaban18$14,267
EntrestoSacubitril/Valsartan13$13,894
FarxigaDapagliflozin Propanediol11$13,388
MyrbetriqMirabegron20$13,336
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,368
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$10,066
JanuviaSitagliptin Phosphate14$7,017
Repatha SureclickEvolocumab11$5,972
Lidocaine13$1,645
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,544
Atorvastatin Calcium91$1,136
Rosuvastatin Calcium65$1,051

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$489$68,30858 claims
Novo NordiskOzempic$617$49,06048 claims
AstraZenecaFarxiga, Breztri Aerosphere$608$23,45425 claims
PfizerEliquis$283$14,26718 claims
NovartisEntresto$114$13,89413 claims
Astellas Pharma US IncMyrbetriq$83$13,33620 claims
GSKTrelegy Ellipta$934$12,36815 claims
MerckJanuvia$191$7,01714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →